ARCHIVES

Phase III Study: Rituxan Improved PFS By 79% In Advanced Follicular Lymphoma

This article is from The Cancer Letter archive.

Vol. 33 No. 12 | December 31, 2010

Download PDF Visit The Full Archive

Related Articles

Chemical, Viral Carcinogenesis Should Not Be Separated: Shimkin

July 14, 1978

Also David Schwartz of Duke University to head NIEHS.

October 29, 2004

NCCS Networker Volume 2 Issue 3, Summer 1988

June 13, 1988

Afinitor and Exemestane More Than Doubles PFS, Reduces Progression Risk by 57 Percent

September 30, 2011

Cancer, AIDS Drug Screening Contracts Ok’d For Recompetition

February 28, 1992

IOM Calls FDA Advisory System Sounds, Suggests Conflict Criteria Changes

March 5, 1993